INTRAOCULAR GROWTH FACTORS AND CYTOKINES IN PATIENTS WITH DRY AND NEOVASCULAR AGE-RELATED MACULAR DEGENERATION

被引:34
|
作者
Muether, Philipp S. [1 ]
Neuhann, Irmingard [2 ]
Buhl, Christoph [1 ]
Hermann, Manuel M. [1 ]
Kirchhof, Bernd [1 ]
Fauser, Sascha [1 ]
机构
[1] Univ Cologne, Ctr Ophthalmol, Dept Vitreoretinal Surg, D-50924 Cologne, Germany
[2] Red Cross Hosp, Eye Dept, Munich, Germany
来源
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES | 2013年 / 33卷 / 09期
关键词
age-related macular degeneration; choroidal neovascularization; drusen; endostatin; intraocular growth factors; platelet-derived growth factor; vascular endothelial growth factor; VEGF; AQUEOUS-HUMOR LEVELS; EPITHELIUM-DERIVED FACTOR; CHOROIDAL NEOVASCULARIZATION; MACULOPATHY; EXPRESSION; MEMBRANES; BEVACIZUMAB; PREVALENCE; ENDOSTATIN; SYSTEM;
D O I
10.1097/IAE.0b013e318285cd9e
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose: To analyze intraocular growth factor and cytokine concentrations in eyes with different stages of age-related macular degeneration (AMD) compared with controls. Methods: The Clinical Age-Related Maculopathy Staging (CARMS) system was used for assignment of patients into the respective categories. Aqueous humor specimens were taken before cataract surgery in 21 controls (CARMS 1) and in 17 early (CARMS 2) and 16 intermediate (CARMS 3) AMD patients. In 18 neovascular (CARMS 5) AMD patients, specimens were taken immediately before anti-vascular endothelial growth factor intravitreal therapy. Luminex multiplex bead assays were conducted for endostatin, angiogenin, vascular endothelial growth factor, platelet-derived growth factor AA, placental growth factor, thrombospondin 2, and fibroblast growth factor a. Results: Vascular endothelial growth factor concentrations were elevated in CARMS 3 (P = 0.037) and tended to be elevated in CARMS 5 (P = 0.093), whereas levels in CARMS 2 (P = 0.425) were similar to CARMS 1. Platelet-derived growth factor levels were diminished in CARMS 2 (P = 0.020), with a trend to lower levels for CARMS 3 (P = 0.099) and CARMS 5 (P = 0.082) compared with CARMS 1. For CARMS 5, antiangiogenic endostatin was elevated (P < 0.002), while antiangiogenic thrombospondin 2 was reduced (P = 0.029). Conclusion: Clinical Age-Related Maculopathy Staging 3 dry AMD was associated with higher vascular endothelial growth factor levels than CARMS 5 neovascular AMD. Therefore, intraocular vascular endothelial growth factor concentrations do not seem to reflect choroidal neovascularization activity in neovascular AMD directly. Platelet-derived growth factor was decreased in most forms of AMD. The antiangiogenic endostatin was exclusively elevated in neovascular AMD, while thrombospondin 2 was reduced. Age-related macular degeneration disease seems to be associated with a generally altered cytokine system.
引用
收藏
页码:1809 / 1814
页数:6
相关论文
共 50 条
  • [1] Neovascular Age-related Macular Degeneration: Intraocular Cytokines and Growth Factors and the Influence of Therapy with Ranibizumab
    Funk, Marion
    Karl, David
    Georgopoulos, Michael
    Benesch, Thomas
    Sacu, Stefan
    Polak, Kaija
    Zlabinger, Gerhard J.
    Schmidt-Erfurth, Ursula
    OPHTHALMOLOGY, 2009, 116 (12) : 2393 - 2399
  • [2] Intraocular and systemic inflammation-related cytokines during one year of ranibizumab treatment for neovascular age-related macular degeneration
    Fauser, Sascha
    Viebahn, Ulrike
    Muether, Philipp S.
    ACTA OPHTHALMOLOGICA, 2015, 93 (08) : 734 - 738
  • [3] Bevacizumab vs ranibizumab for neovascular age-related macular degeneration in Chinese patients
    Li, Jun
    Zhang, Han
    Sun, Peng
    Gu, Feng
    Liu, Zhe-Li
    INTERNATIONAL JOURNAL OF OPHTHALMOLOGY, 2013, 6 (02) : 169 - 173
  • [4] Choroidal neovascular membranes secondary to intraocular tuberculosis misdiagnosed as neovascular age-related macular degeneration
    Invernizzi, Alessandro
    Agarwal, Aniruddha
    Di Nicola, Maura
    Franzetti, Fabio
    Staurenghi, Giovanni
    Viola, Francesco
    EUROPEAN JOURNAL OF OPHTHALMOLOGY, 2018, 28 (02) : 216 - 224
  • [5] An update on the pharmacotherapy of neovascular age-related macular degeneration
    Freund, K. Bailey
    Mrejen, Sarah
    Gallego-Pinazo, Roberto
    EXPERT OPINION ON PHARMACOTHERAPY, 2013, 14 (08) : 1017 - 1028
  • [6] Ranibizumab in neovascular age-related macular degeneration
    Eng, Kenneth T.
    Kertes, Peter J.
    CLINICAL INTERVENTIONS IN AGING, 2006, 1 (04) : 451 - 466
  • [7] Anxiety in Patients with Neovascular Age-related Macular Degeneration
    Weinstein, Orly
    Cohen, Arnon D.
    Levy, Jaime
    Zloto, Ofira
    Freud, Tamar
    Krieger, Israel
    Comaneshter, Doron
    Shemesh, Rachel
    OPHTHALMIC EPIDEMIOLOGY, 2023, 30 (03) : 286 - 292
  • [8] PROFILE OF INTRAOCULAR IMMUNE MEDIATORS IN PATIENTS WITH AGE-RELATED MACULAR DEGENERATION AND THE EFFECT OF INTRAVITREAL BEVACIZUMAB INJECTION
    Agawa, Tsuyoshi
    Usui, Yoshihiko
    Wakabayashi, Yoshihiro
    Okunuki, Yoko
    Juan, Ma
    Umazume, Kazuhiko
    Kezuka, Takeshi
    Takeuchi, Masaru
    Yamauchi, Yasuyuki
    Goto, Hiroshi
    RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2014, 34 (09): : 1811 - 1818
  • [9] Hot Topics in Pharmacotherapy for Neovascular Age-Related Macular Degeneration
    Falavarjani, Khalil Ghasemi
    Sadda, Srinivas R.
    CURRENT PHARMACEUTICAL DESIGN, 2017, 23 (04) : 535 - 541
  • [10] Review of Aflibercept for the Treatment of Neovascular Age-Related Macular Degeneration
    Stewart, Michael W.
    CLINICAL MEDICINE INSIGHTS-THERAPEUTICS, 2013, 5 : 81 - 93